We Venture Capital has invested $6.95 million in Proton Intelligence's Seed round to support the development of its innovative CKM™ technology for monitoring potassium levels in kidney patients.
Information on the Target
Proton Intelligence Inc. is an innovative company headquartered in Vancouver, Canada, with research and development operations based in Melbourne, Australia. The company is at the forefront of healthcare revolution through its development of the CKM™ technology, which offers non-invasive monitoring of potassium levels for kidney patients. This groundbreaking technology is designed to address a critical gap in the management of patients with chronic kidney disease or heart failure, where a third of such patients often discontinue life-saving therapies due to unexpected high potassium events.
Proton's CKM™ technology enables healthcare providers to track potassium levels accurately and continuously, thereby facilitating timely and precise treatment interventions for affected patients. This capability is essential in preventing severe health complications and improving overall outcomes in the management of cardio-kidney-metabolic conditions.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in Canada
The healthcare technology sector in Canada is rapidly evolving, with significant investments flowing into innovative solutions that enhance patient care. As the demand for advanced medical technologies continues to rise, companies like Proton Intelligen
Similar Deals
Sectoral Asset Management, Genesys Capital, Desjardins Capital, Seido Capital, Private Investors → Antegrade Medical Inc.
2025
We Venture Capital
invested in
Proton Intelligence
in 2023
in a Seed Stage deal
Disclosed details
Transaction Size: $7M